Ubs Asset Management Americas Inc Durect Corp Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	BUY	$1.6 - $2.02 $19,222 - $24,268	12,014 Added 5.9%	215,714 $351,000
Q1 2021 May 14, 2021	BUY	$1.86 - $2.87 $63,984 - $98,728	34,400 Added 20.32%	203,700 $403,000
Q4 2020 Mar 01, 2021	BUY	$1.65 - $2.43 $45,540 - $67,068	27,600 Added 19.48%	169,300 $350,000
Q3 2020 Nov 13, 2020	BUY	$1.6 - $2.35 $21,760 - $31,960	13,600 Added 10.62%	141,700 $242,000
Q2 2020 Aug 14, 2020	BUY	$1.33 - $2.76 $170,373 - $353,556	128,100 New	128,100 $297,000

599K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $171M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.